Share Price and Basic Stock Data
Last Updated: December 9, 2025, 2:08 am
| PEG Ratio | -4.95 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Glenmark Life Sciences Ltd has carved a niche for itself within the pharmaceuticals sector, showcasing a robust revenue trajectory. Over the past fiscal year, the company reported sales of ₹12,990 Cr, a commendable increase from ₹12,305 Cr in the previous year. The latest quarterly performance indicates a sequential rise in sales, with ₹3,264 Cr recorded for June 2025, reflecting a strong recovery from a dip in December 2023 when revenues fell to ₹2,507 Cr. The company’s focus on Active Pharmaceutical Ingredients (APIs) seems to be paying off, as evidenced by consistent quarter-on-quarter growth, particularly in the latter half of 2024. However, the dip in December 2023 raises questions about seasonal demand fluctuations or potential operational challenges. With a trailing twelve-month (TTM) revenue standing at ₹13,342 Cr, Glenmark appears well-positioned to leverage its established market presence and operational efficiencies to drive growth further.
Profitability and Efficiency Metrics
Profitability has been a mixed bag for Glenmark Life Sciences, with operating profit margins (OPM) fluctuating significantly. The OPM stood at 18% for FY 2025, a rebound from a concerning low of 10% in FY 2024. However, the journey hasn’t been smooth; the company faced a significant operating loss of ₹209 Cr in December 2023, resulting in an annual net profit of ₹754 Cr, down from ₹994 Cr in the previous year. This inconsistency raises red flags regarding operational efficiency and cost management. The interest coverage ratio (ICR) of 11.90x suggests that the company is comfortably managing its debt obligations, which is a positive sign for investors. Nonetheless, the recent volatility in profits, coupled with a high effective tax rate of 51% in June 2025, emphasizes the need for a closer examination of cost structures and pricing strategies to enhance profitability sustainably.
Balance Sheet Strength and Financial Ratios
Glenmark’s balance sheet reflects a healthy financial position, underpinned by total assets of ₹15,991 Cr and reserves of ₹9,554 Cr. The company has maintained a low debt profile, with borrowings standing at ₹1,224 Cr, translating to a debt-to-equity ratio of just 0.24. This conservative leverage positions Glenmark favorably compared to many peers in the pharmaceuticals sector, allowing for greater financial flexibility. The return on equity (ROE) of 15.8% and return on capital employed (ROCE) of 19.4% indicate efficient utilization of shareholder capital. However, the decline in ROCE to 10% in FY 2024 raises concerns about asset efficiency during that period. Furthermore, the price-to-book value ratio (P/BV) at 4.91x suggests that the stock may be overvalued relative to its book value, which could deter some value-oriented investors.
Shareholding Pattern and Investor Confidence
Investor sentiment towards Glenmark Life Sciences appears mixed, as reflected in its shareholding pattern. Promoters hold a stable 46.64% stake, indicating confidence in the company’s long-term prospects. However, foreign institutional investors (FIIs) have reduced their holdings from 23.19% in December 2022 to 20.73% as of September 2025, suggesting a cautious stance amidst the company’s recent performance volatility. Domestic institutional investors (DIIs), on the other hand, have increased their stake to 18.61%, reflecting some optimism about future prospects. The total number of shareholders has seen a decline from over 3 lakh to around 1.98 lakh, which could indicate a consolidation phase as more investors reassess their positions. This evolving shareholding pattern may influence market perceptions and the stock’s liquidity in the near term.
Outlook, Risks, and Final Insight
Going forward, Glenmark Life Sciences faces a dual-edged sword of opportunities and challenges. On one hand, the potential for growth in the global pharmaceuticals market, particularly in the API segment, remains robust. However, the company’s recent profitability fluctuations and high tax burden pose significant risks. Investors may need to weigh the stability of earnings against the backdrop of rising operational costs and potential market competition. Additionally, the company must address the volatility in its quarterly performances to regain investor confidence. As Glenmark navigates these complexities, it will be essential for stakeholders to monitor developments closely and assess how management addresses these challenges, particularly in cost management and operational efficiency. The stock’s performance will likely hinge on its ability to stabilize earnings and demonstrate a clear path to sustainable growth amidst an evolving market landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Glenmark Life Sciences Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 151 Cr. | 120 | 247/84.3 | 33.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,114 Cr. | 378 | 479/192 | 85.2 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.8 Cr. | 44.2 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 43.9 Cr. | 30.0 | 30.5/17.0 | 105 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,308.71 Cr | 1,152.57 | 51.23 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,777 | 3,018 | 3,100 | 3,001 | 3,036 | 3,207 | 2,507 | 3,063 | 3,244 | 3,434 | 3,388 | 3,256 | 3,264 |
| Expenses | 2,346 | 2,539 | 2,626 | 2,603 | 2,599 | 2,745 | 2,715 | 2,559 | 2,656 | 2,832 | 2,787 | 2,695 | 2,684 |
| Operating Profit | 432 | 479 | 474 | 398 | 437 | 462 | -209 | 504 | 588 | 602 | 600 | 561 | 581 |
| OPM % | 16% | 16% | 15% | 13% | 14% | 14% | -8% | 16% | 18% | 18% | 18% | 17% | 18% |
| Other Income | 183 | 86 | 209 | -696 | -32 | -205 | 87 | 351 | 31 | 39 | 31 | -361 | -297 |
| Interest | 60 | 83 | 97 | 109 | 112 | 121 | 134 | 149 | 40 | 48 | 52 | 67 | 58 |
| Depreciation | 147 | 146 | 152 | 135 | 142 | 141 | 147 | 151 | 118 | 120 | 123 | 125 | 130 |
| Profit before tax | 408 | 337 | 435 | -542 | 151 | -6 | -403 | 555 | 462 | 473 | 456 | 8 | 96 |
| Tax % | 48% | 17% | 33% | -26% | -14% | 997% | -18% | 319% | 26% | 25% | 24% | 45% | 51% |
| Net Profit | 211 | 279 | 291 | -403 | 173 | -62 | -331 | -1,214 | 340 | 354 | 348 | 4 | 47 |
| EPS in Rs | 6.82 | 9.23 | 9.66 | -15.18 | 5.31 | -2.90 | -12.45 | -43.17 | 12.06 | 12.55 | 12.33 | 0.16 | 1.66 |
Last Updated: August 19, 2025, 2:37 pm
Below is a detailed analysis of the quarterly data for Glenmark Life Sciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 3,264.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,256.00 Cr. (Mar 2025) to 3,264.00 Cr., marking an increase of 8.00 Cr..
- For Expenses, as of Jun 2025, the value is 2,684.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2,695.00 Cr. (Mar 2025) to 2,684.00 Cr., marking a decrease of 11.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 581.00 Cr.. The value appears strong and on an upward trend. It has increased from 561.00 Cr. (Mar 2025) to 581.00 Cr., marking an increase of 20.00 Cr..
- For OPM %, as of Jun 2025, the value is 18.00%. The value appears strong and on an upward trend. It has increased from 17.00% (Mar 2025) to 18.00%, marking an increase of 1.00%.
- For Other Income, as of Jun 2025, the value is -297.00 Cr.. The value appears strong and on an upward trend. It has increased from -361.00 Cr. (Mar 2025) to -297.00 Cr., marking an increase of 64.00 Cr..
- For Interest, as of Jun 2025, the value is 58.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 67.00 Cr. (Mar 2025) to 58.00 Cr., marking a decrease of 9.00 Cr..
- For Depreciation, as of Jun 2025, the value is 130.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 125.00 Cr. (Mar 2025) to 130.00 Cr., marking an increase of 5.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 96.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2025) to 96.00 Cr., marking an increase of 88.00 Cr..
- For Tax %, as of Jun 2025, the value is 51.00%. The value appears to be increasing, which may not be favorable. It has increased from 45.00% (Mar 2025) to 51.00%, marking an increase of 6.00%.
- For Net Profit, as of Jun 2025, the value is 47.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Mar 2025) to 47.00 Cr., marking an increase of 43.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.66. The value appears strong and on an upward trend. It has increased from 0.16 (Mar 2025) to 1.66, marking an increase of 1.50.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:15 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,005 | 6,563 | 7,562 | 9,079 | 9,074 | 9,865 | 10,641 | 10,944 | 12,305 | 12,990 | 11,813 | 13,322 | 13,342 |
| Expenses | 4,914 | 5,348 | 6,125 | 7,043 | 7,457 | 8,280 | 8,942 | 8,860 | 9,978 | 10,712 | 10,618 | 10,970 | 10,998 |
| Operating Profit | 1,091 | 1,214 | 1,437 | 2,037 | 1,617 | 1,586 | 1,699 | 2,084 | 2,327 | 2,278 | 1,195 | 2,351 | 2,344 |
| OPM % | 18% | 18% | 19% | 22% | 18% | 16% | 16% | 19% | 19% | 18% | 10% | 18% | 18% |
| Other Income | 11 | -180 | 20 | -44 | 89 | 375 | 191 | 95 | -101 | -449 | 336 | -259 | -587 |
| Interest | 189 | 190 | 179 | 237 | 286 | 335 | 377 | 353 | 298 | 350 | 516 | 207 | 226 |
| Depreciation | 217 | 300 | 234 | 264 | 302 | 326 | 417 | 444 | 487 | 611 | 582 | 486 | 498 |
| Profit before tax | 697 | 544 | 1,044 | 1,491 | 1,119 | 1,301 | 1,096 | 1,382 | 1,441 | 868 | 434 | 1,399 | 1,032 |
| Tax % | 22% | 61% | 29% | 26% | 28% | 29% | 29% | 30% | 31% | 57% | 430% | 25% | |
| Net Profit | 546 | 209 | 743 | 1,109 | 804 | 925 | 776 | 970 | 994 | 377 | -1,434 | 1,047 | 754 |
| EPS in Rs | 19.99 | 7.72 | 26.33 | 39.29 | 28.49 | 32.78 | 27.50 | 34.38 | 33.37 | 10.53 | -53.22 | 37.11 | 26.70 |
| Dividend Payout % | 0% | 26% | 8% | 5% | 7% | 6% | 9% | 7% | 7% | 24% | -5% | 7% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -61.72% | 255.50% | 49.26% | -27.50% | 15.05% | -16.11% | 25.00% | 2.47% | -62.07% | -480.37% | 173.01% |
| Change in YoY Net Profit Growth (%) | 0.00% | 317.22% | -206.24% | -76.76% | 42.55% | -31.16% | 41.11% | -22.53% | -64.55% | -418.30% | 653.38% |
Glenmark Life Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 5% |
| 3 Years: | 3% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 12% |
| 3 Years: | 6% |
| TTM: | 159% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 33% |
| 3 Years: | 74% |
| 1 Year: | 16% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | -1% |
| 3 Years: | -10% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 3:36 pm
Balance Sheet
Last Updated: December 4, 2025, 2:57 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 27 | 27 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
| Reserves | 2,956 | 1,756 | 3,601 | 4,464 | 5,135 | 5,577 | 6,042 | 7,036 | 9,058 | 9,446 | 7,820 | 8,821 | 9,554 |
| Borrowings | 3,267 | 3,800 | 3,988 | 4,724 | 4,639 | 4,449 | 4,869 | 4,986 | 3,962 | 4,627 | 1,231 | 2,473 | 1,224 |
| Other Liabilities | 2,176 | 2,726 | 2,575 | 2,548 | 2,793 | 3,235 | 3,729 | 3,524 | 4,003 | 5,228 | 5,279 | 4,669 | 8,196 |
| Total Liabilities | 8,427 | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,329 | 14,358 | 15,991 | 19,002 |
| Fixed Assets | 3,091 | 2,015 | 2,594 | 2,755 | 3,030 | 3,670 | 5,029 | 5,129 | 5,887 | 6,202 | 4,210 | 4,487 | 5,210 |
| CWIP | 5 | 477 | 543 | 708 | 1,122 | 1,399 | 1,222 | 1,382 | 1,010 | 1,251 | 662 | 835 | 695 |
| Investments | 0 | 17 | 17 | 16 | 15 | 30 | 25 | 25 | 50 | 45 | 790 | 56 | 42 |
| Other Assets | 5,331 | 5,799 | 7,039 | 8,285 | 8,429 | 8,190 | 8,393 | 9,040 | 10,105 | 11,830 | 8,697 | 10,613 | 13,054 |
| Total Assets | 8,427 | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,329 | 14,358 | 15,991 | 19,002 |
Below is a detailed analysis of the balance sheet data for Glenmark Life Sciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 28.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 28.00 Cr..
- For Reserves, as of Sep 2025, the value is 9,554.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,821.00 Cr. (Mar 2025) to 9,554.00 Cr., marking an increase of 733.00 Cr..
- For Borrowings, as of Sep 2025, the value is 1,224.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 2,473.00 Cr. (Mar 2025) to 1,224.00 Cr., marking a decrease of 1,249.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 8,196.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,669.00 Cr. (Mar 2025) to 8,196.00 Cr., marking an increase of 3,527.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 19,002.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15,991.00 Cr. (Mar 2025) to 19,002.00 Cr., marking an increase of 3,011.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 5,210.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,487.00 Cr. (Mar 2025) to 5,210.00 Cr., marking an increase of 723.00 Cr..
- For CWIP, as of Sep 2025, the value is 695.00 Cr.. The value appears to be declining and may need further review. It has decreased from 835.00 Cr. (Mar 2025) to 695.00 Cr., marking a decrease of 140.00 Cr..
- For Investments, as of Sep 2025, the value is 42.00 Cr.. The value appears to be declining and may need further review. It has decreased from 56.00 Cr. (Mar 2025) to 42.00 Cr., marking a decrease of 14.00 Cr..
- For Other Assets, as of Sep 2025, the value is 13,054.00 Cr.. The value appears strong and on an upward trend. It has increased from 10,613.00 Cr. (Mar 2025) to 13,054.00 Cr., marking an increase of 2,441.00 Cr..
- For Total Assets, as of Sep 2025, the value is 19,002.00 Cr.. The value appears strong and on an upward trend. It has increased from 15,991.00 Cr. (Mar 2025) to 19,002.00 Cr., marking an increase of 3,011.00 Cr..
Notably, the Reserves (9,554.00 Cr.) exceed the Borrowings (1,224.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -2.00 | -2.00 | -2.00 | -2.00 | -3.00 | -3.00 | -3.00 | -2.00 | -1.00 | -2.00 | 0.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 131 | 140 | 120 | 97 | 94 | 81 | 83 | 86 | 92 | 115 | 57 | 92 |
| Inventory Days | 191 | 247 | 249 | 299 | 244 | 244 | 211 | 230 | 208 | 203 | 208 | 254 |
| Days Payable | 279 | 379 | 308 | 243 | 225 | 241 | 210 | 226 | 190 | 172 | 210 | 216 |
| Cash Conversion Cycle | 43 | 8 | 61 | 152 | 113 | 85 | 84 | 90 | 110 | 147 | 56 | 129 |
| Working Capital Days | 62 | 47 | 51 | 125 | 99 | 64 | 54 | 67 | 65 | 141 | -2 | 44 |
| ROCE % | 15% | 16% | 19% | 21% | 15% | 15% | 14% | 15% | 16% | 10% | 12% | 19% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Mid Cap Fund | 12,636,078 | 2.67 | 2389.74 | N/A | N/A | N/A |
| Invesco India Midcap Fund | 1,864,031 | 3.78 | 352.53 | N/A | N/A | N/A |
| Invesco India Contra Fund | 1,662,235 | 1.56 | 314.36 | 1,510,869 | 2025-06-29 09:52:49 | 10.02% |
| Axis Midcap Fund | 1,361,025 | 0.8 | 257.4 | N/A | N/A | N/A |
| Invesco India Large & Mid Cap Fund | 1,342,939 | 2.81 | 253.98 | 1,205,107 | 2025-11-03 01:08:21 | 11.44% |
| HDFC Large and Mid Cap Fund | 1,048,046 | 0.7 | 198.21 | N/A | N/A | N/A |
| Mahindra Manulife Multi Cap Fund | 989,000 | 3.09 | 187.04 | N/A | N/A | N/A |
| Mirae Asset Healthcare Fund | 956,043 | 6.41 | 180.81 | 1,013,543 | 2025-06-29 09:52:49 | -5.67% |
| Bandhan Small Cap Fund | 952,877 | 1.04 | 180.21 | N/A | N/A | N/A |
| HDFC Balanced Advantage Fund | 885,046 | 0.16 | 167.38 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 37.11 | -53.22 | 10.53 | 33.37 | 34.38 |
| Diluted EPS (Rs.) | 37.11 | -53.22 | 10.53 | 33.37 | 34.38 |
| Cash EPS (Rs.) | 54.33 | -30.18 | 35.04 | 52.46 | 50.10 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 313.60 | 278.09 | 348.70 | 334.48 | 250.36 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 313.60 | 278.09 | 348.70 | 334.48 | 250.36 |
| Revenue From Operations / Share (Rs.) | 472.08 | 418.62 | 460.36 | 436.08 | 387.85 |
| PBDIT / Share (Rs.) | 87.36 | 72.13 | 91.97 | 88.14 | 75.65 |
| PBIT / Share (Rs.) | 70.13 | 51.50 | 70.31 | 70.89 | 59.93 |
| PBT / Share (Rs.) | 49.58 | 1.29 | 30.78 | 51.08 | 48.99 |
| Net Profit / Share (Rs.) | 37.11 | -50.80 | 13.37 | 35.21 | 34.38 |
| NP After MI And SOA / Share (Rs.) | 37.11 | -53.21 | 10.53 | 33.37 | 34.38 |
| PBDIT Margin (%) | 18.50 | 17.22 | 19.97 | 20.21 | 19.50 |
| PBIT Margin (%) | 14.85 | 12.30 | 15.27 | 16.25 | 15.45 |
| PBT Margin (%) | 10.50 | 0.30 | 6.68 | 11.71 | 12.63 |
| Net Profit Margin (%) | 7.86 | -12.13 | 2.90 | 8.07 | 8.86 |
| NP After MI And SOA Margin (%) | 7.86 | -12.71 | 2.28 | 7.65 | 8.86 |
| Return on Networth / Equity (%) | 11.83 | -19.13 | 3.13 | 10.36 | 13.73 |
| Return on Capital Employeed (%) | 19.62 | 17.01 | 13.84 | 16.13 | 14.83 |
| Return On Assets (%) | 6.52 | -10.45 | 1.53 | 5.51 | 6.21 |
| Long Term Debt / Equity (X) | 0.05 | 0.00 | 0.40 | 0.28 | 0.55 |
| Total Debt / Equity (X) | 0.24 | 0.12 | 0.45 | 0.40 | 0.66 |
| Asset Turnover Ratio (%) | 0.87 | 0.70 | 0.71 | 0.42 | 0.42 |
| Current Ratio (X) | 1.56 | 1.28 | 1.96 | 1.77 | 1.75 |
| Quick Ratio (X) | 1.05 | 0.84 | 1.37 | 1.23 | 1.21 |
| Inventory Turnover Ratio (X) | 4.81 | 1.15 | 1.31 | 1.85 | 1.85 |
| Dividend Payout Ratio (NP) (%) | 6.73 | -4.69 | 23.73 | 7.49 | 7.27 |
| Dividend Payout Ratio (CP) (%) | 4.60 | -7.66 | 7.76 | 4.93 | 4.99 |
| Earning Retention Ratio (%) | 93.27 | 104.69 | 76.27 | 92.51 | 92.73 |
| Cash Earning Retention Ratio (%) | 95.40 | 107.66 | 92.24 | 95.07 | 95.01 |
| Interest Coverage Ratio (X) | 11.90 | 3.94 | 7.42 | 8.34 | 6.04 |
| Interest Coverage Ratio (Post Tax) (X) | 7.86 | -0.80 | 4.27 | 5.21 | 3.62 |
| Enterprise Value (Cr.) | 43947.27 | 26350.45 | 16364.27 | 15087.86 | 16656.12 |
| EV / Net Operating Revenue (X) | 3.30 | 2.23 | 1.26 | 1.23 | 1.52 |
| EV / EBITDA (X) | 17.83 | 12.95 | 6.31 | 6.07 | 7.80 |
| MarketCap / Net Operating Revenue (X) | 3.26 | 2.29 | 1.01 | 1.01 | 1.20 |
| Retention Ratios (%) | 93.26 | 104.69 | 76.26 | 92.50 | 92.72 |
| Price / BV (X) | 4.91 | 3.44 | 1.38 | 1.37 | 1.86 |
| Price / Net Operating Revenue (X) | 3.26 | 2.29 | 1.01 | 1.01 | 1.20 |
| EarningsYield | 0.02 | -0.05 | 0.02 | 0.07 | 0.07 |
After reviewing the key financial ratios for Glenmark Life Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -53.22 (Mar 24) to 37.11, marking an increase of 90.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -53.22 (Mar 24) to 37.11, marking an increase of 90.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 54.33. This value is within the healthy range. It has increased from -30.18 (Mar 24) to 54.33, marking an increase of 84.51.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.60. It has increased from 278.09 (Mar 24) to 313.60, marking an increase of 35.51.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.60. It has increased from 278.09 (Mar 24) to 313.60, marking an increase of 35.51.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 472.08. It has increased from 418.62 (Mar 24) to 472.08, marking an increase of 53.46.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 87.36. This value is within the healthy range. It has increased from 72.13 (Mar 24) to 87.36, marking an increase of 15.23.
- For PBIT / Share (Rs.), as of Mar 25, the value is 70.13. This value is within the healthy range. It has increased from 51.50 (Mar 24) to 70.13, marking an increase of 18.63.
- For PBT / Share (Rs.), as of Mar 25, the value is 49.58. This value is within the healthy range. It has increased from 1.29 (Mar 24) to 49.58, marking an increase of 48.29.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -50.80 (Mar 24) to 37.11, marking an increase of 87.91.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -53.21 (Mar 24) to 37.11, marking an increase of 90.32.
- For PBDIT Margin (%), as of Mar 25, the value is 18.50. This value is within the healthy range. It has increased from 17.22 (Mar 24) to 18.50, marking an increase of 1.28.
- For PBIT Margin (%), as of Mar 25, the value is 14.85. This value is within the healthy range. It has increased from 12.30 (Mar 24) to 14.85, marking an increase of 2.55.
- For PBT Margin (%), as of Mar 25, the value is 10.50. This value is within the healthy range. It has increased from 0.30 (Mar 24) to 10.50, marking an increase of 10.20.
- For Net Profit Margin (%), as of Mar 25, the value is 7.86. This value is within the healthy range. It has increased from -12.13 (Mar 24) to 7.86, marking an increase of 19.99.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.86. This value is below the healthy minimum of 8. It has increased from -12.71 (Mar 24) to 7.86, marking an increase of 20.57.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.83. This value is below the healthy minimum of 15. It has increased from -19.13 (Mar 24) to 11.83, marking an increase of 30.96.
- For Return on Capital Employeed (%), as of Mar 25, the value is 19.62. This value is within the healthy range. It has increased from 17.01 (Mar 24) to 19.62, marking an increase of 2.61.
- For Return On Assets (%), as of Mar 25, the value is 6.52. This value is within the healthy range. It has increased from -10.45 (Mar 24) to 6.52, marking an increase of 16.97.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.05, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has increased from 0.12 (Mar 24) to 0.24, marking an increase of 0.12.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.87. It has increased from 0.70 (Mar 24) to 0.87, marking an increase of 0.17.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has increased from 1.28 (Mar 24) to 1.56, marking an increase of 0.28.
- For Quick Ratio (X), as of Mar 25, the value is 1.05. This value is within the healthy range. It has increased from 0.84 (Mar 24) to 1.05, marking an increase of 0.21.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.81. This value is within the healthy range. It has increased from 1.15 (Mar 24) to 4.81, marking an increase of 3.66.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 6.73. This value is below the healthy minimum of 20. It has increased from -4.69 (Mar 24) to 6.73, marking an increase of 11.42.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 4.60. This value is below the healthy minimum of 20. It has increased from -7.66 (Mar 24) to 4.60, marking an increase of 12.26.
- For Earning Retention Ratio (%), as of Mar 25, the value is 93.27. This value exceeds the healthy maximum of 70. It has decreased from 104.69 (Mar 24) to 93.27, marking a decrease of 11.42.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 95.40. This value exceeds the healthy maximum of 70. It has decreased from 107.66 (Mar 24) to 95.40, marking a decrease of 12.26.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 11.90. This value is within the healthy range. It has increased from 3.94 (Mar 24) to 11.90, marking an increase of 7.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.86. This value is within the healthy range. It has increased from -0.80 (Mar 24) to 7.86, marking an increase of 8.66.
- For Enterprise Value (Cr.), as of Mar 25, the value is 43,947.27. It has increased from 26,350.45 (Mar 24) to 43,947.27, marking an increase of 17,596.82.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.30. This value exceeds the healthy maximum of 3. It has increased from 2.23 (Mar 24) to 3.30, marking an increase of 1.07.
- For EV / EBITDA (X), as of Mar 25, the value is 17.83. This value exceeds the healthy maximum of 15. It has increased from 12.95 (Mar 24) to 17.83, marking an increase of 4.88.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 3. It has increased from 2.29 (Mar 24) to 3.26, marking an increase of 0.97.
- For Retention Ratios (%), as of Mar 25, the value is 93.26. This value exceeds the healthy maximum of 70. It has decreased from 104.69 (Mar 24) to 93.26, marking a decrease of 11.43.
- For Price / BV (X), as of Mar 25, the value is 4.91. This value exceeds the healthy maximum of 3. It has increased from 3.44 (Mar 24) to 4.91, marking an increase of 1.47.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 3. It has increased from 2.29 (Mar 24) to 3.26, marking an increase of 0.97.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.02, marking an increase of 0.07.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Glenmark Life Sciences Ltd:
- Net Profit Margin: 7.86%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 19.62% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.83% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.86
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.05
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 21.6 (Industry average Stock P/E: 51.23)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.24
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.86%
FAQ
What is the intrinsic value of Glenmark Life Sciences Ltd?
Glenmark Life Sciences Ltd's intrinsic value (as of 09 December 2025) is 929.49 which is 51.64% lower the current market price of 1,922.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 54,304 Cr. market cap, FY2025-2026 high/low of 2,286/1,275, reserves of ₹9,554 Cr, and liabilities of 19,002 Cr.
What is the Market Cap of Glenmark Life Sciences Ltd?
The Market Cap of Glenmark Life Sciences Ltd is 54,304 Cr..
What is the current Stock Price of Glenmark Life Sciences Ltd as on 09 December 2025?
The current stock price of Glenmark Life Sciences Ltd as on 09 December 2025 is 1,922.
What is the High / Low of Glenmark Life Sciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Glenmark Life Sciences Ltd stocks is 2,286/1,275.
What is the Stock P/E of Glenmark Life Sciences Ltd?
The Stock P/E of Glenmark Life Sciences Ltd is 21.6.
What is the Book Value of Glenmark Life Sciences Ltd?
The Book Value of Glenmark Life Sciences Ltd is 340.
What is the Dividend Yield of Glenmark Life Sciences Ltd?
The Dividend Yield of Glenmark Life Sciences Ltd is 0.13 %.
What is the ROCE of Glenmark Life Sciences Ltd?
The ROCE of Glenmark Life Sciences Ltd is 19.4 %.
What is the ROE of Glenmark Life Sciences Ltd?
The ROE of Glenmark Life Sciences Ltd is 15.8 %.
What is the Face Value of Glenmark Life Sciences Ltd?
The Face Value of Glenmark Life Sciences Ltd is 1.00.